Business
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET. A live webcast can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sion
About this update from Sionna Therapeutics, Inc.
[{"type":"image","alt":"Sionna Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Sionna Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tV.lxsbkEH4l9r3Dfcm34Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/tV.lxsbkEH4l9r3Dfcm34Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418","width":300,"height":300}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.","length":396,"tagName":"p"},{"type":"text","content":"A live webcast can be accessed in the ‘Investors’ section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.","length":171,"tagName":"p"},{"type":"text","content":"About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developi...